Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.